Aventis Groupe: Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis
Dupixent® (dupilumab)approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis Approximately seven […]